Navigation Links
VaxGen Restructures Board of Directors
Date:5/22/2008

Governance changes intended to support renewed strategic transaction effort

SOUTH SAN FRANCISCO, Calif., May 22 /PRNewswire-FirstCall/ VaxGen, Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, today announced the appointment of two new members to its Board of Directors, and the resignations of three of its current Directors. The new Board appointees are Paul De Stefano, J.D., a principal with the law firm of Fish and Richardson LLC, and a specialist in transactions in the biotechnology and health sciences industries; and Lori F. Rafield, Ph.D., currently an independent consultant specializing in corporate and business development for biotechnology companies and previously a Managing Director with the venture firm of Apax Partners. The Board members resigning are VaxGen's current chairman Randall L-W. Caudill D.Phil., Michel Greco and Myron M. Levine, M.D.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

In conjunction with these changes, VaxGen is reconstituting the Strategic Transactions Committee of the Board. De Stefano and Rafield will serve on this Committee, together with James P. Panek, VaxGen's President and CEO. De Stefano will also be a member of the Board's Audit and Nominating and Governance Committees, while Rafield will serve on the Compensation Committee. Kevin Reilly has been elected Chairman of the Board to replace Dr. Caudill.

"Both Paul and Lori have decades of biotechnology transaction experience." said James P. Panek, VaxGen President and CEO. "I am delighted to welcome two such well-qualified Directors, and look forward to working closely with them as the Company re-evaluates its strategic alternatives. With these governance changes, I believe we are well positioned to move forward on a renewed strategic transaction effort. I'd also like to thank Randall, Michel and Myron for their capable guidance an
'/>"/>

SOURCE VaxGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
3. VaxGen Files First Quarter 2007 Financials
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. VaxGen Files Last Outstanding Periodic Report With SEC
6. VaxGen Addresses MPM Claims in Letter to Stockholders
7. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
10. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
11. VaxGen Reports Financial Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the ... received a Canadian Patent for Inhibition or Reversal ... includes claims using thymosin beta 4, various fragments ... these purposes.  The patent will expire in 2021. ... www.regenerx.com ) RegeneRx is focused ...
(Date:9/30/2014)... 30, 2014  KemPharm, Inc., a clinical-stage specialty ... of proprietary new molecular entity (NME) prodrugs, announced ... Office (USPTO) issued U.S. Patent No. 8,816,083 to ... Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates ... Thereof." The patent, which extends through ...
(Date:9/30/2014)... The custom stainless steel fabrication company HOLLOWAY ... The Boston Area Chapter of ISPE (International Society for ... for Wed., Oct. 1 at Gillette Stadium Clubhouse in ... in ISPE Boston’s long history, with more than 375 ... , HOLLOWAY AMERICA President David Simpson is looking ...
(Date:9/30/2014)... 30, 2014 UFP Technologies, a ... packaging has recently introduced a custom insulated shipping ... . The new insulated shipper solves the issue ... process. UFP Technologies’ BioShell is a universal storage ... storage, handling and shipping. The insulated shipper keeps ...
Breaking Biology Technology:RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3
... Smilodon ranks alongside Tyrannosaurus rex as the ultimate killing ... was a fearsome predator of Ice-Age America,s lost giants. ... debated how this iconic predator used its ferocious fangs ... published today in the US Proceedings of the National ...
... 1 Boston Scientific,Corporation (NYSE: BSX ) will ... quarter ended September 30, 2007 on Friday,October 19, at ... by Jim Tobin, President and Chief Executive,Officer, Paul LaViolette, ... Chief Financial Officer. The live webcast and archived ...
... Space Center,has awarded a five-year, $120-million extension of ... Institute, also known,as NSBRI, of Houston. Under the ... continue biomedical research in support of a,long-term human ... the cooperative agreement began April 1, 1997, with,a ...
Cached Biology Technology:Scientists say sabercat bit like a pussycat 2Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results 2
(Date:9/30/2014)... in almost any aquatic environment on Earth, but when ... are pushed to the limit. The amount of time ... for how different species cope in the future, reveals ... Gothenburg, published in the scientific journal Proceedings of ... apace thanks to increasing levels of greenhouse gases in ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... Calif. Beyond the personal tragedy of chronic alcoholism ... know severe alcoholism stresses the heart and that mitochondria, ... But they don,t know the precise mechanism. Now ... Center of the New York State Department of Health ...
... 22, 2012 -- The first clinical trial of a ... by the Infectious Disease Research Institute (IDRI), a Seattle-based ... diseases of poverty. The Phase 1 trial is taking ... trial planned in India, an epicenter of the disease. ...
... an outbreak of airborne H5N1 influenza in humans needs to ... can safely continue H5N1 research and share the results among ... mBio , the online open-access journal of the American Society ... been at the center of heated discussions in science and ...
Cached Biology News:A change of heart 2First vaccine against fatal visceral leishmaniasis enters clinical trial 2First vaccine against fatal visceral leishmaniasis enters clinical trial 3Opinion: H5N1 flu is just as dangerous as feared, now requires action 2Opinion: H5N1 flu is just as dangerous as feared, now requires action 3
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Latanoprost EIA Antiserum EIAs neutrophils antisera enzyme immunoassays reagents...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: